Fortis Group Advisors LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 145.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,916 shares of the company's stock after buying an additional 43,213 shares during the period. Fortis Group Advisors LLC's holdings in Novo Nordisk A/S were worth $3,496,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of NVO. Godfrey Financial Associates Inc. bought a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $25,000. Scarborough Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $26,000. WealthCollab LLC lifted its stake in shares of Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company's stock valued at $27,000 after purchasing an additional 260 shares during the period. Jackson Grant Investment Advisers Inc. bought a new position in shares of Novo Nordisk A/S in the 4th quarter worth $29,000. Finally, Quaker Wealth Management LLC grew its stake in shares of Novo Nordisk A/S by 186.0% during the fourth quarter. Quaker Wealth Management LLC now owns 615 shares of the company's stock worth $31,000 after purchasing an additional 400 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.
Novo Nordisk A/S Stock Performance
Shares of Novo Nordisk A/S stock opened at $45.91 on Friday. The stock's fifty day simple moving average is $47.36 and its 200 day simple moving average is $44.51. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $204.99 billion, a PE ratio of 11.23, a PEG ratio of 4.23 and a beta of 0.76. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The firm had revenue of $11.98 billion during the quarter. On average, research analysts predict that Novo Nordisk A/S will post 3.41 EPS for the current year.
Novo Nordisk A/S Cuts Dividend
The firm also recently disclosed a dividend, which will be paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th will be issued a dividend of $0.5786 per share. This represents a dividend yield of 254.0%. The ex-dividend date is Monday, August 17th. Novo Nordisk A/S's payout ratio is 42.79%.
Wall Street Analyst Weigh In
A number of research firms recently commented on NVO. Weiss Ratings upgraded Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. BMO Capital Markets restated a "market perform" rating and set a $47.00 target price on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Zacks Research raised Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday. Citigroup reiterated a "neutral" rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Finally, Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 20th. Four equities research analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $64.94.
Read Our Latest Stock Analysis on Novo Nordisk A/S
More Novo Nordisk A/S News
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: Oral Wegovy adoption is emerging as a potential catalyst. Jim Cramer highlighted accelerating pill prescriptions and argued that Wall Street’s initial negative reaction to Novo’s quarterly performance may have overlooked the company’s underlying strength. Jim Cramer Reevaluates Novo Nordisk as Wegovy Pill Adoption Accelerates
- Positive Sentiment: Unusually high call-option activity suggests some traders are positioning for a rebound: investors purchased roughly 100,752 calls, about 58% above typical volume. This is a market signal rather than a change in fundamentals.
- Positive Sentiment: Novo’s CEO Mike Doustdar said the obesity-drug market will not be dominated by a single company, arguing that patients will value differentiated treatments and that oral options could broaden demand. Novo CEO Says Obesity Market Won’t Be Winner-Take-All Battle With Lilly
- Neutral Sentiment: Zacks Research upgraded Novo Nordisk from “strong sell” to “hold,” indicating reduced bearishness but not a bullish recommendation. Erste Group also issued a fiscal-2026 earnings estimate, though no estimate details were provided.
- Negative Sentiment: Eli Lilly is gaining obesity-drug market share, creating concern that Lilly’s injectable and oral therapies could widen its competitive advantage even as Novo reports record prescriptions for oral Wegovy. Can Novo Nordisk’s GLP-1 Pill Momentum Offset Lilly’s Growing Edge?
- Negative Sentiment: The company’s chief executive acknowledged Lilly’s market-share gains, while an escalating marketing dispute highlights intensifying competition in the strategically important weight-loss market. Novo Nordisk Escalates Weight-Loss War With Eli Lilly
About Novo Nordisk A/S
(
Free Report)
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
